What Australian sky watchers can expect as the Perseids return for 2025
Dubbed 'the best meteor shower of the year' by experts, the Perseids are one of the busiest showers with about 50 to 100 meteors seen per hour, according to NASA.
The event produces fast, bright streaks and occasional fireballs, larger bursts of light caused by bigger chunks of space debris burning up in Earth's atmosphere.
The meteors come from debris left behind by comet 109P/Swift-Tuttle, which last passed through the inner solar system in 1992 and is almost twice the size of the asteroid believed to have wiped the dinosaurs from Earth.
As Earth moves through this trail of dust and rock each year, the particles slam into our atmosphere at high speeds, creating the familiar flashes of light in the night sky.
NASA says the Perseids are best viewed in the pre-dawn hours, when the sky is darkest and the shower's radiant point, the constellation Perseus, is higher above the horizon, but they can sometimes be seen from about 10pm.
But there's a catch for Aussie viewers: The best views are in the Northern Hemisphere.
Only those in the far north of Australia may catch a glimpse of the brighter meteors, and even then, the brightness of the moon will reduce visibility significantly.
Those in southern Australia will likely miss out altogether.
The shower runs from July 17 to August 23, with peak activity expected about August 12.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
7 minutes ago
- ABC News
High school students introduced to robotics to encourage STEM careers
Ahmad Elbashety would be finished his schooling by now, but had to flee his home in Gaza during his final year of study. After a year he describes as being extremely hard and uncertain, he was able to come to Australia and recommence his schooling. Joining year 10 at Bankstown Senior College in Sydney's south-west, Ahmad has taken part in a study that teaches high school students coding and robotics. He says the program has given him a career to aspire to and something to focus on. "I didn't know much about robotics or programming, but now I really enjoy it," Ahmad said. He is one of 40 year 10 students in a program run by Australian Catholic University (ACU) that has targeted students from low socio-economic and refugee backgrounds. The new study is examining whether teaching students coding and robotics can spark a sustained interest in STEM. Students from schools in Western Sydney were given a week-long crash course learning how to operate a robot using easy-to-learn drag-and-drop blocks of code on an electronic tablet. Caroline Chisholm College student Aliyah Chilly said the course was the first time she had used coding to drive a robot. She said the drag-and-drop block coding was easy to use for a beginner. "The blocks are made for you, you've just got to fill in the information like degrees, the speed and how far you want it [the car] to go," Aliyah said. Following the week-long course, the students were given a tablet and a robot and will respond to surveys and complete tasks over the next nine months to see if they still have that interest. A federal government education grant funded the tablets and robots. ACU associate professor of IT Walayat Hussain said jobs of the future would demand knowledge of how to work with robots. "You can see AI has been embedded everywhere," Dr Hussain said. Dr Hussain is running the study along with Dr Mehdi Rajaeian and Dr Mahmoud Bekhit. They are managing the project in their spare time. Dr Hussain said that without training in AI and robotics, young people could face reduced job prospects in their future. "I believe that every human should have equal access to this technology," he said. National figures show STEM education outcomes have been slow to progress in recent years. The Australian Curriculum, Assessment and Reporting Authority found only 57 per cent of year 6 students attained the science proficiency standard in 2023. In 2006, just 54 per cent of year 6 students attained the standard. Progress on attaining science proficiency standards has also been slow among year 10 students. Just 54 per cent of year 10 students met the standard in 2023, compared to 50 per cent in 2018. The researchers hope programs like this could help turn figures like these around. The study's first week may have already inspired some interest in STEM careers. Ahmad hopes he can get a university scholarship and continue studying engineering. St Agnes Catholic student Isabella Sukkarieh wants to become a biomedical or industrial engineer. "I will need to design products and then I'll need to use programs like the ones we're using here to show, basically, proof that the product works," Isabella said. Meanwhile, Caroline Chisholm College student Aliyah Chilly is interested in bringing her knowledge of robotics to child care to introduce the skills to an even younger generation than hers. "I feel like it's something important for kids to experience," Aliyah said.
ABC News
2 hours ago
- ABC News
Barnaby Joyce pushing to scrap Net Zero target
Australia is being urged to remain ambitious in its bid to reduce carbon emissions, as former Nationals leader pushes his Nationals colleagues to scrap the Net Zero emissions target by 2050. It comes as a CSIRO report shows that renewables still have the lowest cost range of any new electricity generation.
News.com.au
3 hours ago
- News.com.au
Dr Boreham's Crucible: Oncology-focused Qbiotics hopes to crawl through IPO ‘window of opportunity'
Like other IPO candidates – and the list is growing – private oncology drug developer Qbiotics has been closely watching the trajectory of Virgin Australia since the airlines June 24 ASX listing. The biggest float since fast food chain Guzman y Gomez spiced up things in June last year, Virgin's initial public offer (IPO) has been seen as a barometer of broader investor appetite for new offerings. With Virgin shares holding nicely at cruising altitude, is it time for the Brisbane-based Qbiotics to debut? Qbiotics chief Stephen Doyle says IPO timing has never been right in the past, but the company now is positioned to crawl through the window of opportunity when it opens. In March the company appointed Jeffries and Bell Potter as joint lead managers for the putative float, and it is getting its financial reporting into shape. 'We have done the due diligence and prospectus drafting … all the things you need to do for an IPO,' Doyle says. 'At the end of the day it's picking the right time with the right catalysts to create value for shareholders.' Tapping nature's pharmacy The company may have found such a catalyst, having last month reported encouraging results from its phase II soft tissue sarcoma (STS) trial. The study road tests Qbiotics tigilanol tiglate (EBC-46), which derived from the depths of the Daintree rainforest. The company says tigilanol tiglate has a 'multi-factorial mode of action', including activating the protein kinase C. This leads to the disruption of the tumour's blood supply, while also stimulating a local inflammatory response. Separate from this, tigilanol tiglate can directly kill cancer cells within the tumour, in a way that promotes the development of anti-tumour immunity. This is like how a vaccine works. Qbiotics has phase II programs for both soft tissue sarcoma and head and neck cancers (HNCs). It also has less advanced programs in venous leg ulcers and anti-microbial and anti-inflammatory applications. Dogged effort wins canine approval Qbiotics has an approved product, Stelfonta, to treat canine mast cell tumours. The current standard of care is surgery - but anaesthesia is dangerous for older dogs and brachycephalic breeds (short snouted ones such as bulldogs, boxers, pugs and shih tzus). Stelfonta is administered by injection directly into the tumour mass. The European Medicines Agency approved Stelfonta in January 2020, followed by the US Food and Drug Administration in November 2020 and the Australian Pesticides and Veterinary Medicines Authority in July 2021. Stelfonta is distributed by the French group Virbac, which is responsible for all sales and marketing, while Qbiotics provides the finished product at a suitable margin. Doyle says the veterinary drug showed Qbiotics could take a product all the way from discovery to commercialisation. 'It was also a derisking strategy,' he says. 'The canine is a good surrogate for the human setting and that has been the case. 'We have some good safety and efficacy data in well over 20,000 dogs'. Stelfonta recently won a label expansion in the UK, for use in resectable mast tumours (not just inoperable ones). The story to date Qbiotics was co-founded by research scientist Dr Victoria Gordon and husband and forest ecologist Dr Paul Reddell. Both founders were employed by the Commonwealth Scientific and Industrial Research Organisation, but in 2000 Dr Gordon busted out to form Ecobiotics. The duo then formed Qbiotics in 2010. -Ecobiotics merged with Qbiotics in 2017. The pair stumbled on tigilanol tiglate when fossicking in rainforest in the Atherton Tablelands of Far North Queensland. They observed that animals spat out the seed of the blushwood tree, pointing to a non-toxic deterrent preventing the critters from eating and thus destroying the seed. Qbiotics isolated tigilanol tiglate and tests for anti-cancer activity in animals proved safe and effective. Doyle was appointed in early September 2024 after Dr Gordon stepped down, but she remains on the board. At the time, Mark Fladrich and David Phillips were appointed, while Andrew Denver and Prof Bruce Robinson stepped down. The company's chair, Dr Susan Foden died suddenly in early November and Mr Fladrich assumed the chair role. The board previously included former ASX and Cochlear chair Rick Holliday-Smith, Cochlear chief financial officer Neville Mitchell and erstwhile Macquarie Bank CEO Nicholas Moore. Taking the low road and the high road A Scottish pharmacist, Doyle has a long history with big pharma companies in medical and commercial roles. Since peregrinating to Australia at the end of 1999 on a working holiday visa, Doyle has held roles with Janssen, Novartis, Sanofi and Boehringer Ingelheim. He had lengthy stints in Paris, Singapore and Shanghai, before being poached by the smaller Aslan Pharmaceuticals (based in the Lion City). 'I liked the idea of roll up your sleeves and multi-tasking, whereas with big pharma you tend to get pigeon-holed,' he said. Doyle joined Qbiotics partly because he liked the idea of returning to Australia, notably Brisbane, but also because of the buzz of developing a drug. 'The risk of biotech is quite exciting,' he says. 'It's not for everyone. If you want a nice stable job ... get a job at Pfizer.' Soft tissue sarcoma Soft tissue sarcoma (STS) is a rare cancer that generally forms as a painless tumour in any bodily soft tissue. The company says there were 128,000 new cases of STS globally in 2023, with the incidence growing at about half a per cent per year. The US Food and Drug Administration has granted tigilanol tiglate orphan drug status for this indication. Conducted at New York's Memorial Sloan Kettering Cancer Centre, stage one of the phase IIa trial covered 10 evaluable patients with advanced STS. The study achieved an objective response rate of 80% in injected tumours, with eight patients having a complete ablation or partial ablation (reduction of 30% or more). Of the injected tumours, 22 out of 27 (81%) showed complete or partial ablation (14 complete). 'None of the 14 completely ablated tumours recurred at six months, indicating tigilanol tiglate may provide durable responses,' the company says. The trial moves to an expanded second stage, with another 40 patients targeted. Doyle says there around 80 to 120 STS sub types, but the company intends to narrow its work to the most common varieties. Head and neck cancers (HNC) Qbiotics currently is recruiting in Australia and UK for the HNC phase II trial. As with the STS trial, it is single-arm and open label. An earlier 19-patient phase I/II trial met safety and tolerability goals. Head and neck cancers are a portfolio of cancers afflicting the mouth, nose, throat, voice box, sinuses, and salivary glands. Doyle says HNCs are challenging in at least two ways. For a start, they occur close to vital organs and vessels. Secondly, patients tend to be from lower socio-economic areas. For instance, mouth cancer is quite prevalent in India and may result from chewing betel nut. Smoking and chewing tobacco and alcohol are key risk factors with mouth and voice box cancers. Oro-pharyngeal cancers are linked to the human papillomavirus. The company hopes to release top-line data later his year. Here, there and everywhere … Doyle says tigilanol tiglate is an 'interesting molecule' because it has multiple modes of action. This includes some evidence of an abscopal effect, over and above the drug's direct effect on the tumour. The abscopal effect is when localised cancer therapies lead to the shrinkage or even disappearance of tumours elsewhere in the body. Not surprisingly, the immune system is thought to transmit the tumour kill signals. In an 'off study' observation the abscopal effect was seen in a melanoma patient, in an earlier phase I 'all comers' study. (The company carried out two melanoma studies, one of them a dose-escalation effort in combo with Keytruda and the other a monotherapy). The company is carrying out exploratory work on the abscopal effect in the STS and HNC programs and hopes to present data at an upcoming congress of learned peers. In the background, the company is also undertaking a dose escalation and safety study for venous leg ulcers, which remain stubbornly hard to treat. A semi-synthetic variant, this one would be a drug rather than a device, which would be rare in wound healing. Finances and performance Qbiotics' unlisted status hasn't prevented the company from raising large wads of money: $194 million since inception, plus $60 million of tax incentives and government grants. In early 2021, the company raised a hefty $85 million, with investment firm TDM Growth Partners accounting for $50 million (existing holders took up the rest). At the end of December 2024, the company had cash of $39 million. 'We have enough money to deliver on our outlined programs, including part two of the STS trial and a venous leg ulcer study,' Doyle says. In the December half year, the company generated $1.16 million from Stelfonta sales, which 'continued to be lower than expected'. With its level of disclosure, Qbiotics' annual report looks more like the work of a listed company. With no listed mechanism – or not yet anyway – buyers and sellers can trade separately via Dr Boreham's diagnosis Doyle says Qbiotics' strategy has been to generate data in multiple tumours, including melanoma, to broaden the company's commercial appeal. 'For us it is about creating proof of concept and evidence in multiple solid tumour types, to make us attractive for partnering. 'Our sweet spot is phase II or IIb, but we need to find a big partner … with the necessary infrastructure and resources to run multiple registration studies targeting multiple solid tumour types.' He says Qbiotics is not yet at the point of having to hone its indications of interest. 'We are small nimble and get to wear multiple hats, but ultimately we are limited by resources.' In its 25th year, Qbiotics offers enough goings-on to maintain the interest of the company's circa 2,600 shareholders ahead of the listing. For the record, Grandview Research values the STS market at US$1.26 billion in 2023 and reckons the HNC sector will be worth US$5.2 billion by 2030. The vet market is estimated at US$100 million. That's decent enough, but a morsel compared to the human oncology opportunities. At a glance Qbiotics is a public unlisted company Chief executive officer: Stephen Doyle Shares on issue: 489,026,611 Financials (half year to December 31, 2024): revenue $1.16 million (up 6%), government grants $3.89 million (-4%), loss of $9.3 million (previously an $8.5 million loss), cash on hand $39.2 million (down 15%). Board: Mark Fladrich (chair), Doyle, Dr Victoria Gordon (co-founder), Dr Paul Reddell (co-founder), David Phillips, Sergio Duchini Major shareholders: TDM Growth Partners 11%, founders and staff 13%, remaining top 20 24%, remaining shareholders 52%
